Three-dimensional models of non-steroidal ligands: A comparative molecular field analysis

Steroids

Volumn 71, Issue 6, 2006, Pages 417-428

  Menezes, Irwin R A ^a   Leitão, Andrei ^a   Montanari, Carlos A ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

3D QSAR; CoMFA CoMSIA; Estrogen receptor; GRID Almond; SERMs

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTRADIOL; ESTROGEN RECEPTOR; LIGAND; RALOXIFENE;

ARTICLE; CHEMICAL MODEL; COMPARATIVE MOLECULAR FIELD ANALYSIS; LIGAND BINDING; MOLECULAR INTERACTION; PREDICTION; PROTEIN DOMAIN; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BINDING SITES; BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL LINE, TUMOR; COMPUTER SIMULATION; ESTROGENS; FEMALE; HUMANS; HYDROGEN BONDING; INHIBITORY CONCENTRATION 50; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RALOXIFENE; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

PRUNUS DULCIS;

EID: 33646139411     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2006.01.001     Document Type: Article

References (46)

1. Veeneman G.H. Non-steroidal subtype selective estrogens. Curr Med Chem 12 (2005) 1077-1136
2. Tyulmenkov V.V., and Klinge C.M. Interaction of tetrahydrocrysene ketone with estrogen receptor α and β indicates conformational differences in receptor subtypes. Arch Biochem Biophys 381 (2000) 135-142
3. Lin X., and Huebner V. Non-steroidal ligands for steroid hormone receptors. Curr Opin Drug Discov Devel 3 (2000) 383-398
4. Katzenellenbogen B.S., Montano M.M., Ekena K., Herman M.E., and McInerney E.M. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 44 (1997) 23-38
5. Compton D.R., Carlson K.E., and Katzenellenbogen J.A. Pyrazolo[1,5-a]pyrimidines as estrogen receptor ligands: defining the orientation of a novel heterocyclic core. Bioorg Chem Lett 14 (2004) 5681-5684
6. Gustafsson J.-A. Therapeutic potential of selective estrogen receptor modulators. Curr Opin Chem Biol 2 (1998) 508-511
7. Dutertre M., and Smith C.L. Molecular mechanisms of selective estrogen receptor modulators (SERM) action. J Pharmacol Exp Ther 295 (2000) 431-437
8. Gasco M., Argusti A., Bonanni B., and Decensi A. SERMs in chemoprevention of breast cancer. Eur J Cancer 41 (2005) 1980-1989
9. Katzenellenbogen B.S., and Katzenellenbogen J.A. Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta-regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2 (2000) 335-344
10. Nilsson S., and Gustafsson J.-A. Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res 2 (2000) 360-366
11. Golbraikh A., Bernard P., and Chrétien J.R. Validation of protein-based alignment in 3D quantitative structure-activity relationships with CoMFA models. Eur J Med Chem 35 (2000) 123-136
12. Cramer R.D., Patterson D.E., and Bunce J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110 (1988) 5959-5967
13. Kubinyi H. QSAR and 3D QSAR in drug design. Part 1: methodology. Drug Discov Today 2 (1997) 457-467
14. Kubinyi H. QSAR and 3D QSAR in drug design. Part 2: applications and problems. Drug Discov Today 2 (1997) 538-546
15. Klebe G., and Abraham U. Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries. J Comput Aided Mol Des 13 (1999) 1-10
16. Pastor M., Cruciani G., McLay I., Pickett S., and Clementi S. Grid-independent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J Med Chem 43 (2000) 3233-3243
17. Grese T.A., Pennington L.D., Sluka J.P., Adrian M.D., Cole H.W., Fuson T.R., et al. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J Med Chem 41 (1998) 1272-1283
18. Grese T.A., Cho S., Finley D.R., Godfrey A.G., Jones C.D., Lugar III C.W., et al. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem 40 (1997) 146-167
19. Morris G.M., Goodsell D.S., Huey R., and Olson A.J. Distributed automated docking of flexible ligand to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10 (1996) 293-304
20. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engström O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
21. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28 (1985) 849-857
22. Cratteri P., Romanelli M.N., Cruciani G., Bonaccini C., and Melani F. GRIND-derived pharmacophore model for a series of alpha-tropanyl derivative ligands of the sigma 2-receptor. J Comput Aided Mol Des 18 (2004) 361-374
23. Broto P., Moreau G., and Vandycke C. Molecular structures: perception, autocorrelation descriptor and SAR studies. Autocorrelation descriptor. Eur J Med Chem 19 (1984) 66-70
24. Anzali S., Barnickel G., Krug M., Sadowski J., Wagener M., Gasteiger J., et al. The comparison of geometric and electronic properties of molecular surfaces by neural networks: application to the analysis of corticosteroid-binding globulin activity of steroids. J Comput Aided Mol Des 10 (1996) 521-534
25. Riganelli D., Valigi R., Costantino G., Baroni M., and Wold S. Autocorrelation as a tool for a congruent description of molecules in 3D QSAR studies. Pharm Pharmacol Lett 3 (1993) 5-8
26. Napolitano E., Fiaschi R., Carlson K.E., and Katzenellenbogen J.A. 11.beta-substituted estradiol derivatives, potential high-affinity carbon-11-labeled probes for the estrogen receptor: a structure-affinity-relationship study. J Med Chem 38 (1995) 429-434
27. Poupaert J.H., Lambert D.M., Vamecq J., and Abul-Hajj Y.J. Molecular modeling studies on 11-β-aminoethoxyphenyl and 7-α-aminoethoxyphenyl estradiols. Evidence suggesting a common hydrophobic pocket in estrogen receptor. Bioorg Med Chem Lett 5 (1995) 839-842
28. Waller C.L., Oprea T.I., Chae K., Park H.-K., Korach K.S., Laws S.C., et al. Ligand-based identification of environmental estrogens. Chem Res Toxicol 9 (1996) 1240-1248
29. Henke B.R., Consler T.G., Go N., Hale R.L., Hohman D.R., Jones S.A., et al. A new series of estrogen receptor modulators that display selectivity for estrogen receptor β. J Med Chem 45 (2002) 5492-5505
30. Klebe G., Abraham U., and Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37 (1994) 4130-4146
31. Levenson A.S., and Jordan V.C. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (Aspartate) in the estrogen receptor. Can Res (1998) 581872-581875
32. Kastenholz M.A., Pastor M., Cruciani G., Haaksma E.E.J., and Fox T. GRID/CPCA: a new computational tool to design selective ligands. J Med Chem 43 (2000) 3033-3044
33. Tominaga Y. Comparative study of class data analysis with PCA-LDA, SIMCA, PLS, ANNs and k-NN. Chemom Intell Lab Syst 49 (1999) 105-115
34. Gao H., Katzenellenbogen J.A., Garg R., and Hansch C. Comparative QSAR analysis of estrogen receptor ligands. Chem Rev 99 (1999) 723-744
35. Gao H., Williams C., Labute P., and Bajorath J. Binary quantitative structure-activity relationship (QSAR) analysis of estrogen receptor ligands. J Chem Inf Comput Sci 39 (1999) 164-168
36. Pike A.C.W., Brzozowski A.M., Hubbard R.E., Bonn T., Thorsell A.-G., Engström O., et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 18 (1999) 4608-4618
37. Aliau S., Mattras H., Richard E., Bonnafous J.-C., and Borgna J.-L. Differential interactions of estrogens and antiestrogens at the 17β-hydroxyl or counterpart hydroxyl with histidine 524 of the human estrogen receptor α. Biochemistry 41 (2002) 7979-7988
38. Levenson A.S., MacGregor Schafer J.I., Bentrem D.J., Pease K.M., and Craig Jordan V. Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351. J Steroid Biochem Mol Biol 76 (2001) 61-70
39. Anstead G.M., Carlson K.E., and Katzenellenbogen J.A. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62 (1997) 268-303
40. Tong W., Perkins R., Xing L., Welsh W.J., and Sheehan D.M. QSAR models for binding of estrogenic compounds to estrogen receptor α and β subtypes. Endocrinology 138 (1997) 4022-4025
41. Sippl W., and Holtje H.D. Structure-based 3D-QSAR-merging the accuracy of structure-based alignments with the computational efficiency of ligand-based methods. Theochem 503 (2000) 31-50
42. Wolohan P., and Reichert D.E. CoMFA and docking study of novel estrogen receptor subtype selective ligands. J Comput Aided Mol Des 17 (2003) 313-328
43. Wolohan P., and Reichert D.E. Use of binding energy in comparative molecular field analysis of isoform selective estrogen receptor ligands. J Mol Graph Mod 23 (2004) 23-38
44. Klinge C.M., Traish A.M., Driscoll M.D., Hilf R., and Bambara R.A. Site-directed estrogen receptor antibodies stabilize 4-hydroxytamoxifen ligand, but not estradiol, and indicate ligand-specific differences in the recognition of estrogen response element DNA in vitro. Steroids 61 (1996) 278-289
45. Sippl W. Receptor-based 3D QSAR analysis of estrogen receptor ligands-merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. J Comput Aided Mol Des 14 (2000) 559-572
46. Sippl W. Binding affinity prediction of novel estrogen receptor ligands using receptor-based 3-D QSAR methods. Bioorg Med Chem 10 (2002) 3741-3755